Rabeprazole Sodium + DomperidoneThird Party Manufacturing in India

Rabeprazole Sodium + Domperidone combines two distinct mechanisms to target both the acid and motility components of gastrointestinal disorders. Rabeprazole sodium, a proton pump inhibitor, is a prodrug that is converted to its active sulfenamide form in the acidic environment of gastric parietal cell canaliculi. The active metabolite irreversibly binds to cysteine residues on the H⁺/K⁺-ATPase enzyme, permanently inhibiting the final step of gastric acid secretion. This results in profound and sustained suppression of both basal and stimulated acid output, lasting up to 24 hours or longer. Domperidone, a peripheral dopamine D₂ receptor antagonist, works through an entirely different pathway. It blocks dopamine receptors in the chemoreceptor trigger zone and at the gastric level, increasing lower esophageal sphincter pressure and enhancing gastric antral and duodenal peristalsis. This prokinetic action accelerates gastric emptying, reduces esophageal acid exposure time, and prevents reflux of gastric contents. Domperidone does not readily cross the blood-brain barrier, minimizing central nervous system side effects. Together, rabeprazole addresses the acid hypersecretion while domperidone resolves the underlying motility dysfunction, providing comprehensive symptom relief for patients with acid reflux and dyspeptic disorders.

Therapeutic Uses

Rabeprazole Sodium + Domperidone is prescribed for the treatment of:

• Gastroesophageal Reflux Disease (GERD): For patients with moderate to severe GERD where both acid suppression and improved gastric motility are needed, particularly those with persistent regurgitation and heartburn despite PPI monotherapy.
• Functional Dyspepsia: For the management of epigastric pain, postprandial fullness, early satiety, and bloating associated with functional dyspepsia where impaired gastric accommodation and delayed emptying contribute to symptoms.
• Peptic Ulcer Disease: As part of combination therapy for gastric and duodenal ulcers where associated gastroparesis or delayed gastric emptying complicates management.
• Gastroparesis: For symptomatic relief in patients with diabetic or idiopathic gastroparesis presenting with nausea, vomiting, and postprandial discomfort.
• NSAID-Related Dyspepsia: For patients on long-term NSAID therapy who develop both gastric irritation and motility-related symptoms.

Why Manufacturers Choose Rabeprazole Sodium + Domperidone

This fixed-dose combination is one of the most prescribed gastrointestinal formulations in the Indian market, driven by the high prevalence of GERD and dyspepsia in the population. Rabeprazole offers faster onset of action compared to other PPIs, making it a preferred choice for clinicians. The combination is available in both immediate-release and sustained-release formulations, with strengths of 20mg + 10mg and 20mg + 30mg SR respectively, allowing manufacturers to offer differentiated products for different patient segments. The molecules are well-established with proven safety profiles and stable supply chains for raw materials. Third party manufacturers with WHO-GMP certified facilities can efficiently produce this combination at scale, serving PCD franchise networks across India and export markets in Asia and Africa where acid-related disorders remain highly prevalent.

This makes Rabeprazole Sodium + Domperidone one of the most sought-after combinations for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.